

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

AUSTAR

奥星

Austar Lifesciences Limited

奥星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6118)

PROFIT WARNING

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 and the information currently available to the Board, the Group is expected to record a profit attributable to the owners of the Company of not less than RMB43 million for the six months ended 30 June 2022, as compared to the profit attributable to the owners of the Company of approximately RMB218 million for the six months ended 30 June 2021.

The expected shortfall in profit attributable to owners of the Company was mainly attributable to the fact that for the six months ended 30 June 2021, the Group had recognised one-off net gain (before income tax) of approximately RMB199 million from the Group’s disposal of its 60% equity interest in a then joint venture of the Group which took place in the corresponding period. Based on the Group’s assessment during the audit for the year ended 31 December 2021, taking into account the tax effect, such one-off gain is approximately RMB176 million (the “**Gain on Disposal of JV**”).

For illustration purpose, without taking into account the Gain on Disposal of JV, the profit attributable to owners of the Company for the six months ended 30 June 2021 was approximately RMB42 million. The Company considers a comparison between the profit attributable to the owners of the Company (without taking into account the Gain on Disposal of JV) for the six months ended 30 June 2021 and 2022 may present a more comprehensive and meaningful picture regarding the performance of the Group for its shareholders. On such basis, it is noted that the Group’s financial performance during the six months ended 30 June 2022 has

slightly improved as compared with that for the six months ended 30 June 2021.

The information contained in this announcement is only based on the preliminary assessment by the management of the Company by information currently available to the Group including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 and is not based on any figure or information which has been audited or reviewed by the Company's auditors and may be subject to adjustments and changes. Details of the Group's financial information and performance will be disclosed when the Group's interim results for the six months ended 30 June 2022 are announced, which is expected to be published in late August 2022.

Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 5 August 2022

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.